BD Resumes ChloraPrep™ Shipments After Resolving FDA-Related Hold
BDX sits 16% above its 52-week low of $127.536.
Summary
Becton Dickinson announced the resumption of ChloraPrep™ shipments in the U.S. following additional release testing, confirming all tests were acceptable and no patient safety signals were identified.
Key Events · Legal and Risk Events · BDX
-
Shipments Resumed
Becton Dickinson has resumed shipments of ChloraPrep™ in the U.S.
-
Testing Acceptable
Additional final release testing for ChloraPrep™ has been completed and found acceptable.
-
No Patient Safety Signals
The company confirmed there have been no patient safety signals related to the products.
-
Resolution of Prior Hold
This action resolves the voluntary ship hold initiated on May 6, 2026, in response to an FDA Warning Letter for the El Paso manufacturing facility.
Analysis · BDX · Industrial Applications And Services
This filing provides a positive update on a previously disclosed product hold for ChloraPrep™ and PurPrep™ due to an FDA Warning Letter. The resumption of shipments and confirmation of no patient safety signals remove a regulatory overhang and mitigate potential revenue loss and reputational risk associated with the initial hold.
At the time of this filing, BDX was trading at $148.41 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $40.9B. The 52-week trading range was $127.54 to $187.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.